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Human cytomegalovirus (HCMV) is a significant pathogen in immunocompromised
individuals, with the potential to cause fatal pneumonitis and colitis, as well as increasing
the risk of organ rejection in transplant patients. With the advent of new anti-HCMV drugs
there is therefore considerable interest in using virus sequence data to monitor emerging
resistance to antiviral drugs in HCMV viraemia and disease, including the identification of
putative new mutations. We used target-enrichment to deep sequence HCMV DNA from
11 immunosuppressed pediatric patients receiving single or combination anti-HCMV
treatment, serially sampled over 1–27 weeks. Changes in consensus sequence and
resistance mutations were analyzed for three ORFs targeted by anti-HCMV drugs and
the frequencies of drug resistance mutations monitored. Targeted-enriched sequencing
of clinical material detected mutations occurring at frequencies of 2%. Seven patients
showed no evidence of drug resistance mutations. Four patients developed drug
resistance mutations a mean of 16 weeks after starting treatment. In two patients,
multiple resistance mutations accumulated at frequencies of 20% or less, including
putativemaribavir and ganciclovir resistancemutations P522Q (UL54) andC480F (UL97).
In one patient, resistance was detected 14 days earlier than by PCR. Phylogenetic
analysis suggested recombination or superinfection in one patient. Deep sequencing
of HCMV enriched from clinical samples excluded resistance in 7 of 11 subjects and
identified resistance mutations earlier than conventional PCR-based resistance testing in
2 patients. Detection of multiple low level resistance mutations was associated with poor
outcome.
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INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous
betaherpesvirus with significant disease-causing potential
in immunocompromised patients, including children with
congenital immune deficiencies or immune suppression
following solid organ or bone marrow transplantation. As
well as causing pneumonitis, colitis, retinitis, and uveitis
(Rafailidis et al., 2008) all of which contribute to HCMV-
related mortality, HCMV disease also increases the risk of
allograft vasculopathy and graft rejection, and significantly
increases treatment costs (Hiwarkar et al., 2013). Children are at
particular risk from HCMV, with over 25% of primary HCMV
infections in the UK occurring in childhood (Patrick et al.,
2014). Up to 16% of patients on prolonged anti-HCMV therapy
develop drug resistance (Couzi et al., 2012; Shmueli et al.,
2014), many of them with mutations which cause multi-drug
resistance (Hantz et al., 2010). However, it may be that not all
the mutations that cause resistance are known and this may
lead to underestimation of drug resistance in patients failing
therapy.
Three drugs are currently licensed for HCMV prophylaxis
and treatment, including ganciclovir (GCV), foscarnet (FOS),
cidofovir (CDV); brincidofovir (the oral derivative of cidofovir),
and letermovir are in phase III clinical trials; maribavir (MBV)
is available on a compassionate use basis. Treatment failure
occurs in between 20 (Asberg et al., 2007) and 50% (van
der Beek et al., 2012) of HCMV cases, necessitating drug
changes and in some cases the use of adoptive immunotherapy.
Genetic evidence of drug resistance can guide clinical decision
making (Houldcroft, 2015) but current methods have technical
limitations. Sanger sequencing of PCR amplicons only reliably
detects drug resistance mutations that are present at frequencies
of 20% or more (Sahoo et al., 2013). Deep sequencing of
PCR amplicons has enabled detection of minority resistance
variants at frequencies as low as 1% (Görzer et al., 2010)
which could lead to earlier detection of HCMV resistance and
better treatment. However, PCR and nested PCR are known
to generate mutations which could make the identification of
low level resistance mutations more difficult (Depledge et al.,
2011). To minimize this problem, and to capture the genes
currently implicated in antiviral resistance simultaneously, we
made use of novel target enrichment (Depledge et al., 2011)
and deep sequencing to analyse the UL27, 54, and 97 genes in
serial samples from patients with prolonged HCMV viraemia
despite anti-HCMV therapy. In this study, we include 11
retrospectively identified patients from Great Ormond Street
Hospital for Children who had high HCMV loads for 2
weeks or longer, with clinician suspicion of anti-viral drug
resistance.
Abbreviations: ART, Artusenate; BCDV, Brincidofovir; CAEBV, Chronic
active EBV; CDV, Cidofovir; HCMV, Human cytomegalovirus; CMV-IVIG,
Cytomegalovirus intravenous immune globulin; CTL, Cytotoxic T cells; FOS,
Foscarnet; GCV, Ganciclovir; GOSH, Great Ormond Street Hospital for Children,
UK; LEF, Leflunomide; LTV, Letermovir; MBV, Maribavir; VGCV, Valganciclovir;
WB, Whole blood.
MATERIALS AND METHODS
Ethics and Sample Collection
Whole blood samples were stored at Great Ormond Street
Hospital for Children (GOSH) at −80◦C. These residual
samples were collected as part of the standard clinical care at
GOSH, and subsequently approved for research use through the
UCL Partners Infection DNA Bank by the NRES Committee
London Fulham (REC reference: 12/LO/1089). All samples
were anonymised. Eleven patients with HCMV viral loads that
remained unchanged or rose despite 2 weeks of first line anti-
HCMV therapy were selected. Twenty samples from six patients
(B [5], C [2], H [4], I [4], J [4], and M [1]) were tested for
UL97 and/or UL54 resistance mutations by PCR and Sanger
sequencing at reference laboratories. Samples with sufficient
material for DNA extraction (200 µl) were analyzed.
DNA Extraction, Library Construction,
Targeted Enrichment, and Sequencing
Total DNA was extracted from 200 µl each sample using the EZ1
Virus kit and EZ1 XL extraction system (Qiagen) or DNA Blood
Mini kit (Qiagen) according tomanufacturer’s instructions. Virus
loads were established by an in-house National Health Service
(NHS) diagnostic qPCR assay (GOSH). To determine IU/ml, the
copies/ml value is divided by 4.
SureSelectXT Target Enrichment: RNA
Baits Design
A library of 120-mer RNA baits spanning 115 GenBank
HCMV whole and partial genome sequences were designed
using the PATHSEEK consortium’s (http://www.pathseek.eu/)
in-house PERL script. Baits specificity was verified by BLASTn
searches against the Human Genomic plus Transcript database.
33809 unique custom-designed HCMV baits were uploaded to
SureDesign and synthesized by Agilent Technologies.
SureSelectXT Target Enrichment: Library
Preparation, Hybridisation, and Enrichment
Total DNA from clinical samples was quantified using the Qubit
dsDNA HS assay kit (Life Technologies, Q32854) and between
200–500 ng of DNA was sheared for 150 s, using a Covaris E220
focused ultra-sonication system (PIP 175, duty factor 5, cycles
per burst 200). End-repair, non-templated addition of 3′ poly A,
adapter ligation, hybridisation, PCR (12 cycles pre-capture and
18 or 22 cycles post capture), and all post-reaction clean-up steps
were performed according to the SureSelectXTAutomated Target
Enrichment for Illumina Paired-End Multiplexed Sequencing
200 ng protocol (version F.2) on the Bravo platformWorkStation
B (Agilent Technologies). All recommended quality control steps
were performed on the 2200 TapeStation (Agilent Technologies).
Samples were sequenced using the Illumina MiSeq platform.
The presence of a subset of novel SNPs was confirmed
by Sanger sequencing of PCR amplicons (GATC, Germany;
Source Biosciences, UK; Manchester Medical Microbiology
Partnership, UK; PHE, UK; or the Royal Free Hospital Virology
Department, UK).
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Sequence Assembly and Variant Analysis
Reads were trimmed to remove adapter sequences. Total reads
were mapped to the HCMV reference sequence Merlin (RefSeq
ID NC_006273) ORFs UL27, 54, and 97 using CLC Genomics
Workbench 8.0.3 (Qiagen). Minority variants were called if: the
base was sequenced at least five times; the variant was present in
at least five reads (including two forward and two reverse reads);
and it was present at a frequency of at least 2% (or 1% for bases
sequenced over 1000 times). The read direction filter significance
was 0.05 and the relative read direction filter significance was
0.01. Variants were identified using published lists of HCMV
resistance mutations (Chou, 2011, 2015a,b; Hakki et al., 2011;
Göhring et al., 2015).
Phylogenetic Analysis
Consensus sequences were aligned using ClustalW (Thompson
et al., 2002) and manually corrected in MEGA6 if necessary.
Phylogenetic reconstructions were performed using MEGA6
maximum likelihood analysis (Tamura-Nei model, 1000
bootstraps, default settings, Tamura et al., 2013). Sequences
from the following HCMV genomes were used: NC_006273.2
(Merlin), KU317610.1 (AD169), JX512198.1 (Davis), AY223527.1
(Towne), GU937742.1 (Toledo), KJ872542.1 (PAV21),
HQ380895.1 (JHC), KJ361971.1 (UKNEQAS1), KJ426589.1
(Han), KP745728.1 (BE/4/2010), KP745718.1 (CZ/1/2011).
RESULTS
The duration of HCMV positivity and treatment for each of
the 11 patients is shown in Table 1. Using SureSelect target
enrichment we recovered sequence mapping to the UL27, 54,
and 97 genes directly from all the clinical diagnostic samples
in a single reaction without the need for virus isolation or
PCR of overlapping genome fragments. A sample read mapping
plot for each ORF is shown in Supplementary Figure 1. Details
of mapping and coverage relative to virus genome copies/ml
blood are shown in Supplementary Table 1 and Supplementary
Figure 2.
From deep sequencing results we were able to stratify patients
into two groups: those with no evidence of developing resistance
mutations despite receiving long term antiviral treatment (A, C,
D, G, J, K, L); and those patients who developed known HCMV
resistance mutations: either fixed (H and M) or at low level
(B and I). We plotted viral load, drugs received and mutations
over time for each of these patients (Figure 1; Supplementary
Figure 3).
Comparison of Patients With and Without
Drug Resistance Mutation
Comparing the four patients who developed resistance (B, H,
I, and M) versus the seven who did not, the mean duration of
treatment was longer in those who developed resistance [171
(standard deviation (SD) 79) vs. 101 (SD 70) days], the median
number of antiviral drugs higher (3.5 vs. 2), the peak viraemia
higher (2.16 × 107 vs. 5.36 × 106 virus copies/ml blood) and
mean duration of viraemia was greater [257 (SD 89) vs. 172 (SD
63)]. Apart from the comparison between duration of viremia
(p = 0.048, Student’s T-test), the other differences discussed
above between the resistance and no resistance groups did not
achieve statistical significance. Time to control of viremia in those
who survived was faster in the two patients (H and M) with
resistance: 118 days (SD 47) vs. 131 days (SD 85) in patients
A, D, G, K, and L. Mean total lymphocyte counts (TLC) were
persistently low in patients B, I, and J who died i.e., 0.46 (SD 0.56)
as compared with patients A, D, G, H, K, L, and M who survived
and controlled their viremia to below 1000 copies/ml, mean TLC
1.26 (SD 0.85).
Patterns of Resistance Mutations
Patients B, H, I, and M developed known drug resistance
mutations in UL54 and UL97 during treatment (Figure 1;
Table 2). The mean time to mutation detection was 115 days
(range 18–171) following the start of antiviral treatment. The
mutations detected are shown in Figure 2. Patient H carried
no baseline resistance mutations by deep-sequencing analysis,
but Sanger sequencing detected fixed resistance mutation L501I
(CDV and GCV resistance) in ORF UL54 on day 18 of treatment
(day 43 post-admission). This mutation was not detected by
Sanger sequencing on day 56 of treatment despite continued
GCV; the patient also received FOS throughout this period. The
patient developed a mutation, G598D, in UL97 on day 81 post-
admission (treatment day 56) which has previously been seen
in patients failing GCV therapy, detected by Sanger sequencing.
However, the phenotype of this mutation without concurrent
UL54 mutations has yet to be demonstrated by marker transfer
(Gilbert et al., 2011). Samples taken on days 43 and 81 post-
admission were not available for follow-up deep-sequencing,
but neither mutation was detected by deep sequencing on
days 5, 11, 14, and 18 post-admission. No previously reported
UL27 anti-viral resistance mutations were detected, although a
number of SNPs of unknown function were present, reported
in Supplementary Table 2, and stop codons were present
in UL27 sequences from patients I and L (Supplementary
Figure 4A).
Patient M responded to FOS treatment with a reduction of
viral load from∼250 k copies/ml to∼50 k copies/ml over 4 days,
following the failure of GCV therapy caused by the fixed UL97
mutation H520Q known to cause an 8-fold (or greater) increase
in GCV resistance (Chou et al., 2002; Göhring et al., 2015). This
mutation was initially detected by reference laboratory resistance
testing, and no sample remained for follow-up deep sequencing.
This fixed mutation was detected 43 days after GCV therapy was
withdrawn, by deep sequencing.
In contrast, patients B and I developed multiple low frequency
UL54 and UL97 drug resistance mutations after 112 and 171
days of treatment respectively. Neither patient was able to
control their HCMV, and both eventually died of HCMV-related
complications. In patient I, the first resistance mutation at
position A809V in UL54 which is associated with HCMV growth
rate attenuation (Chou et al., 2007) was detected at a frequency
of 26% 171 days after starting GCV. This mutation declined in
frequency to∼5% following withdrawal of GCV. The cessation of
GCV and start of FOS and CDVwas accompanied by a rise in the
GCV UL97 resistance mutation M460I to 96% together with the
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UL54 resistance mutations Q578L (∼3-fold FOS resistance) and
K513N (12-fold CDV resistance) which rose to over 80% within
46 days. This pattern suggests that the M460I GCV resistance
mutation was linked on the same virus to the UL54 resistance
mutations which were selected for by FOS and CDV. The rising
frequency of UL54 mutations was accompanied by a rise in
HCMV load from 104 to 107 gc/ml. Patient I died with evidence
of extensively drug-resistant HCMV, carrying multiple fixed and
low frequency resistance mutations to CDV, GCV, and FOS. PCR
based resistance testing did not detect resistance until day 225,
when only K513N was detected, although on day 171 Q578L,
E756D, A809V, and M460I were at frequencies greater than 10%.
One days 217 and 241, target-enriched deep sequencing detected
L802M to be present at a frequency of 5%, whereas this mutation
was not detected by Sanger sequencing until day 238 (68 days
later), reported as a “mixture” by the reference laboratory. The
reference laboratory did not report the presence of Q578L,
H729Y (<2%), E756D, A809V, T838A (<2%) or M460I.
A similar picture emerged in Patient B. Although resistance
mutations were not detectable at >2% until after day 84
following the start of treatment, multiple low frequency (<40%)
resistance mutations to GCV, FOS, and CDV, with which the
patient had been treated rapidly developed thereafter (Figure 1).
PCR and Sanger sequencing failed to detect these low level
resistance mutations, with the exception of the GCV (D588N)
substitution which was picked up Sanger sequencing 14 days
after it became detectable by target enriched deep sequencing.
Despite a persistently high and increasing viral load, none of the
low level resistance mutations rose to fixation (peak frequency
< 45%). The introduction of MBV resulted in the decline of
the majority of low frequency GCV, FOS, and CDV mutations
(D301N, D588N and V715M in UL54 and M460I, C592G and
C607Y in UL97). In contrast T409M in UL97 rose in frequency
from 2% on day 175 (43 days after commencing MBV) to 39% at
the point of treatment withdrawal. Mutation T409M is known to
confer cross-resistance to MBV and GCV.
Putative Novel Drug Resistance Mutations
Potential new resistance mutations were only seen in patient B.
Mutations P522Q in UL54 and C480F in UL97 were detected
at days 119 (P522Q) and 175 (C480F), i.e., 14 days before
and 42 days following the introduction of MBV, respectively,
with the former increasing to 84% by day 193 (60 days
following the start of MBV treatment) and the latter also
increasing over time. P522Q and C480F have not previously
been reported as resistance mutations although variants P522S
and P522A are associated with GCV and CDV resistance (Chou,
2008), and C480R is associated with increased resistance to
methylenecyclopropane nucleoside analogs (Komazin-Meredith
et al., 2014). C480F appeared at a frequency of 5% at
approximately the same time as the known MBV mutation
T409M, rising to 58% by day 193 (60 days of MBV treatment).
P522Q appeared first of the previously undetected mutations and
rose rapidly to fixation following initiation of MBV treatment.
The appearance of these three mutations was accompanied by
rising viral load, suggesting that all three may confer resistance
to MBV.
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FIGURE 1 | Viraemia and anti-viral therapy in patients who developed drug resistance. In patients B and I, multiple drug-resistance mutations accrue over
time at a range of frequencies, associated with a multi-drug resistance phenotype and patient death. Patients H and M developed single fixed resistance mutations
and recovered from HCMV disease. ORF locations of each mutation are Table 1. Red arrows: samples deep sequenced by target enrichment. Blue arrows: samples
sequenced only by reference laboratory (PCR + Sanger sequencing) leaving insufficient material for target enriched deep sequencing. Blue open circles: bone marrow
or thymus transplant, or gene therapy given. Left Y axes: log10 virus copies/ml blood. Right Y axes: variant frequency. X axis: time since admission (days).
STOP CODONS, INSERTIONS, AND
DELETIONS
Patients I and L (despite never having received MBV) showed
evidence of fixed truncating mutations in UL27 (Supplementary
Figure 4A) both of which would be predicted to confer resistance
and/or growth attenuation (Chou, 2009; Hakki et al., 2011). In
patient G, a minority stop codon (∼10%) was detected at amino
acid position 512 in UL54 day 63 post-admission, but was not
detected in subsequent samples from this patient (Supplementary
Figure 4B).
In samples from a number of patients, we detected low-
frequency frame shift mutations in ORF UL54, at frequencies of
between 2 and 13%: A (<5%); B (<10%); C (<6%); D (<12%);
H (10%); and K (13%) (Supplementary Figure 5). Many of these
mutations were lost over time, or replaced by different frame
shifts, suggesting they are unfit.
Phylogenetic Analysis of Sequences from
Patients with Multi-Drug Resistance
To examine further the complex drug resistance patterns seen
in patients B and I, we constructed a phylogenetic tree for
each of the three target regions, including all samples from
these patients and 11 publically available HCMV genomes
from GenBank (Figures 3A–C). For patient B, UL27 consensus
sequences clustered in different parts of the tree in a time
dependent manner (Figure 3C). The consensus sequences of
genes UL54 and UL97 show change over time in patients B
and I that is compatible with sequence evolution due to anti-
viral drug pressure (Garrigue et al., 2016). In Patient B the
changes in phylogenetic clustering for UL27 occurred after
the start of MBV on day 133, and may reflect recombination
or re-infection with a second strain of HCMV in this
patient.
DISCUSSION
Persistent HCMV viraemia is associated with poor outcomes in
immunosuppressed patients, including those undergoing bone
marrow (Hiwarkar et al., 2013) and solid organ transplantation,
and treatment with anti-HCMV drugs is indicated. HCMV
viraemia carries significant economic costs, estimated at
£22,500 ($32,000) per pediatric bone marrow transplant patient
(Hiwarkar et al., 2013). To explore treatment failure, testing
for resistance mutations and if necessary a change in therapy
is recommended if the viral load remains the same or rises
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TABLE 2 | All detected mutations (deep sequencing and Sanger sequencing).
UL54 UL97
Patient Known resistance Novel mutations Known resistance Novel mutations
A None D759N None None
B D301N; D588N†; V715M P383S; P522Q†; C592S; R593S; T700P T409M; M460I; C592G; C607Y C480F
C None 782 frame shift; 853 frame shift None None
D C988F
G None C211F; E235K; E944D; S897L; D898N None S512STOP
H L501I* None G598D*‡ None
I K513N†; Q578L; E576D; L802M†; A809V M393L; A987V M460I None
J None None None None
K None None None I429F
L None None
M None H520Q†
*Detected only by Sanger sequencing (sample unavailable for deep sequencing).
†
Detected by deep sequencing and Sanger sequencing.
‡
Resistance phenotype unclear without concurrent UL54 mutations (Gilbert et al., 2011).
after 2 (Boeckh and Ljungman, 2009) or 3 (van der Beek et al.,
2012) weeks of treatment. Changes in treatment may also be
prompted by side effects, and bone marrow function particularly
in hematological stem cell transplant recipients. In this study
we used deep sequencing to investigate drug resistance patterns
in persistently viremic patients requiring prolonged treatment.
Notwithstanding persistent viraemia, seven patients showed no
sign of drug resistance and six of them were able to control
their viremia to below 103 gc/ml while on treatment. Patients
who developed resistance had higher viremia, lower lymphocyte
counts, more drugs and longer duration of antiviral treatment,
although numbers were too small for these differences to be
significant. Overall, these data support the findings of others,
that development of drug resistance mutations are associated
with poor control of viremia and represent a poor prognostic
indicator in immunosuppressed patients receiving treatment for
HCMV; two of four patients developing resistance mutations
died as compared with one of seven who remained resistance-
free. Notwithstanding these findings, the two patients H and M,
in whom resistance mutations rose rapidly to fixation, responded
to a change in treatment and controlled their viremia (two qPCR
results < 103 gc/ml) within a mean of 17 weeks. In patient M
the H520Q resistance mutation to GCV in ORF UL97 persisted
despite withdrawal of the drug, suggesting that this variant
remained fit despite the H520Q mutation.
By contrast, where we identified multiple mutations occurring
simultaneously, in patients B and I, this was associated with
profound treatment failure and death from HCMV-related
disease. Observations from deep-sequencing of PCR amplicons
suggest that multiple resistance mutations occurring at sub-
fixation levels can contribute to a drug-resistant phenotype
(Chou et al., 2014) and this is consistent with the evidence,
particularly in patient B in whom high HCMV viral loads
persisted in the presence of multiple often low frequency
mutations (Figure 1). One explanation is that low frequency
drug resistance mutations are distributed throughout the viral
population resulting in many relatively unfit resistant viruses,
none of which can outcompete the others (Chou et al., 2014).
A similar pattern in seen in patient I, in whom a change from
GCV to CDV appears to have selected for one set of resistance
mutations in favor of another, perhaps because these mutations
arose on different populations of the virus within this patient.
Further evidence for this comes from mouse studies making use
of cells infected with multiple murine CMV strains. These strains
trans-complement one another, increasing overall viral fitness
(Cicin-Sain et al., 2005). Both patients I and B showed a rapid rise
in resistance mutations in response to treatment changes, with
concomitant loss of others. This pattern, particularly in patient
B for whom more samples were available, is consistent with
low level persistence of multiply resistant viruses which rapidly
replicate under the selective pressure of a new drug. Conventional
PCR and Sanger sequencing failed on at least two occasions to
detect any of these mutations, apart from the D588N which was
present at a frequency of 9%. Deep sequencing is therefore able
to detect potentially important drug resistance that is missed by
conventional methods. For example the P552Q mutation was
detected at frequencies of 1.67% (day 119), 4% (day 126), and
10.64% (day 133), prior to the start of MBV on day 133. Similarly,
PCR and Sanger sequencing of samples from patient I missed
multiple drug resistance mutations at frequencies of 2–41%, 54
days after these mutations became detectable by target-enriched
sequencing.
The speed with which the virus became resistant in patient
B and the rapid loss of four drug resistance mutations in
UL97 and UL54, suggested strain replacement rather than de
novo mutation and prompted us to examine the possibility of
mixed infection. The change in phylogenetic clustering for UL27
sequences following the introduction of MBV confirmed this
suspicion. HCMV is known to be highly recombigenic (Sijmons
et al., 2015), and in this case, without whole genome analysis,
we are unable to distinguish the possibility of recombination,
re-infection, or reactivation of a pre-existing secondary strain.
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reported as having drug resistance phenotypes or mutations with drug resistance phenotypes (G598D, Gilbert et al., 2011) when combined with concurrent UL54
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FIGURE 3 | Phylogenetic trees of (A) UL54, (B) UL97, and (C) UL27
nucleotide sequences from the patients with multiple drug-resistance
mutations (B and I) and 11 laboratory and wild-type HCMV strains.
Maximum likelihood analysis was performed with MEGA6, generating
(Continued)
FIGURE 3 | Continued
a tree with 1000 replicates. Bootstrap values of 55 or above are shown. (A)
UL54 phylogenetic tree, showing evolution of patient sequences. Changes in
the consensus sequences of patients B and I due to high-frequency drug
resistance mutations emerging during treatment drive the evolution of their
phylogenetic position. (B) UL97 phylogenetic tree, showing evolution of patient
sequences. Changes in the consensus sequences of patients B and I due to
high-frequency drug resistance mutations emerging during treatment drive the
evolution of their phylogenetic position. (C) UL27 phylogenetic tree. Samples
from patients B do not cluster monophyletically. No previously-reported
resistance mutations were detected within patient B sequences (the only
patient to receive maribavir).
In summary we have demonstrated that deep sequencing of
HCMV ORFs UL27, 54, and 97 could be achieved directly from
whole blood with virus loads in the range 80,000–65,000,000
copies/ml without prior culture or PCR. We were able to detect
resistance mutations occurring at 2% or more in patients with
viraemia persisting at levels of ≥104 gc/ml for 2 weeks or more,
comparable to other deep sequencing-based approaches (e.g.,
Görzer et al., 2010; Garrigue et al., 2016). Our data suggest
that in contrast to amplicon and Sanger sequencing, our deep
sequencing can exclude resistance in patients with persistently
high levels of viraemia, thereby providing a measure of support
prolonging current antiviral treatment or returning to them at
a later date if further treatment is needed. Where resistance
mutations are detected, we observed two patterns, rapid
development of fixed resistance with clearance of virus following
a change in treatment, and development of multiple sub-fixation
resistance mutations, with potentially poorer outcome. Further
investigation is needed to determine whether these patterns
are indeed predictive of outcome. We do not yet understand
why multiple minority drug resistance mutations arise in some
patients. Multiple minority variants, which are likely to be
better detected using deep sequencing methods, appeared to
complicate treatment to a greater extent than single fixed
resistance mutations. In our patients multiple low level drug
mutations was associated with poor prognosis probably because
they increased the risk that a change in drug would select for a
pre-existing mutation. Deep-sequencing of HCMV allows us to
characterize these mutations and could be used to inform which
drugs are given earlier in treatment, or to highlight those patients
for whom additional non-pharmacological interventions such as
withdrawal of immunosuppression, or the use of virus-specific
cytotoxic T lymphocytes are most appropriate.
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